Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST)

9518 Background: MPNSTs are rare soft tissue tumors (STS) that are relatively resistant to chemotherapy. 26% have epidermal growth factor receptor (EGFR) amplification. In preclinical studies, NF1/...